Maynard Um
-
-
-
-
-
-
-
uniQure BV (QURE) PT Raised to $71 at Stifel
-
-
-
-
-
-
-
uniQure plans UK regulatory filing for Huntington's disease gene therapy
-
-
-
-
-
-
-
RBC Capital Upgrades uniQure BV (QURE) to Outperform
-
-
-
-
-
-
-
Cantor Fitzgerald Downgrades uniQure BV (QURE) to Neutral following FDA recommendation
-
-
-
-
-
-
-
Options with increasing option implied volatility: MSTU XXRP ETHU QURE MSTZ BITX
-
-
-
-
-
-
-
uniQure BV (QURE) PT Lowered to $33 at Mizuho
-
-
-
-
-
-
-
uniQure BV (QURE) PT Lowered at RBC Capital After a 'Disappointing Regulatory Update'
-
404,874 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

